This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is a Beat in Store for Alexion (ALXN) This Earnings Season?
by Zacks Equity Research
Impressive sales of Alexion's blockbuster drug, Soliris might lead the company toward an earnings beat in Q1.
Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings?
by Zacks Equity Research
Bristol-Myers (BMY) is scheduled to report Q1 earnings on Apr 26.
The Zacks Analyst Blog Highlights: IBM, McDonald's, Gilead, Phillips 66 and Lam Research
by Zacks Equity Research
The Zacks Analyst Blog Highlights: IBM, McDonald's, Gilead, Phillips 66 and Lam Research
Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics
by Zacks Equity Research
The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.
Gilead (GILD) Presents Encouraging Data on NASH Therapies
by Zacks Equity Research
Gilead Sciences (GILD) announces encouraging data from a proof-of-concept study on experimental combination NASH therapies at The International Liver Congress 2018 in Paris.
Bristol-Myers Collaborates With Harvard Fibrosis Network
by Zacks Equity Research
Bristol-Myers (BMY) announces a research collaboration agreement with Harvard Fibrosis Network to discover and develop potential new therapies for fibrotic diseases, including fibrosis of the liver and heart.
Alexion (ALXN) to Acquire Wilson Therapeutics for $855M
by Zacks Equity Research
Alexion (ALXN) announces that the company will acquire Sweden-based Wilson Therapeutics for $855 million, the latest company to join the ongoing acquisitions spree in the biotech sector.
Pfizer Inks New CAR-T Deal, In Talks With P&G for Unit Sale
by Zacks Equity Research
Pfizer (PFE) out-licenses CAR-T assets to Allogene Therapeutics to expedite development. CNBC report says Pfizer in talks with P&G regarding sale of its Consumer Healthcare unit.
The Zacks Analyst Blog Highlights: United Technologies, Medtronic, Gilead, Hewlett Packard and Yum! Brands
by Zacks Equity Research
The Zacks Analyst Blog Highlights: United Technologies, Medtronic, Gilead, Hewlett Packard and Yum! Brands
Celgene Loses 17.8% in 3 Months: Time to Reshuffle Portfolio?
by Zacks Equity Research
Things have not been going Celgene's (CELG) way as the company has suffered a series of setbacks. The stock has lost 17.8% in the last three months.
3 Sell-Rated Drug Stocks Investors Should Avoid for Now
by Zacks Equity Research
Despite a fairly upbeat performance of the pharma and biotech sector, caution has to be exercised before choosing a stock for investment as a few drug companies are struggling to revive business.
Is Gilead Sciences (GILD) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Gilead Sciences Inc. (GILD) stock is a good choice for value-oriented investors right now from multiple angles.
Bull of the Day: Regeneron (REGN)
by Kevin Cook
Key pharma franchises in a bustling pipeline have shares looking attractive again at 17X and 15% EPS growth
3 Biotech Stocks With Rising Earnings Estimates Post Q4
by Zacks Equity Research
The biotech industry performed reasonably well in Q4. Hence, it is a good idea to select stocks from the sector which saw positive estimate revisions post Q4 earnings release.
Gilead Sciences (GILD) Down 3.4% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Gilead Sciences (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Round Up: Regeneron Submits sBLA, Biogen to Withdraw Zinbryta
by Zacks Equity Research
The biotech sector was in focus last week with these stories - FDA's acceptance of Regeneron's Dupixent's application for asthma, Biogen and partner AbbVie's decision to withdraw multiple sclerosis drug among others.
Gilead Announces Positive Data on New HIV Therapy Biktarvy
by Zacks Equity Research
Gilead (GILD) announces encouraging data from a phase III study, on its new HIV therapy, Biktarvy, at the 2018 Conference on Retroviruses and Opportunistic Infections in Boston.
Biotech ETFs Head to Head: XBI vs. IBB.
by Zacks Equity Research
Head-to-head comparison of two Biotech ETFs, XBI and IBB.
The Zacks Analyst Blog Highlights: Gilead, BNY Mellon, State Street, Alliant Energy and Dillard's
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead, BNY Mellon, State Street, Alliant Energy and Dillard's
Biotech Stock Round Up: Celgene Suffers Setback, Gilead Teams Up with Sangamo
by Zacks Equity Research
The major news in the biotech sector in the last five trading sessions include the FDA's refusal to file letter for Celgene Corporation's (CELG) ozanimod while Gilead Sciences, Inc.'s (GILD) announced an agreement with Sangamo Therapeutics.
Top Analyst Reports for Gilead, BNY Mellon & State Street
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Gilead (GILD), BNY Mellon (BK) and State Street (STT).
Intercept (ICPT) Q4 Earnings & Sales Lag on Dull Ocaliva
by Zacks Equity Research
Intercept (ICPT) missed on both earnings and revenues in the fourth quarter as Ocaliva sales were drab due to safety issues of the drug.
Intercept Starts OCA Trial for NASH Patients With Cirrhosis
by Zacks Equity Research
Intercept (ICPT) initiates a randomized phase III trial, REVERSE, on obeticholic acid in subjects with compensated cirrhosis due to non-alcoholic steatohepatitis.
Glaxo's (GSK) Begins Phase III HIV Two-Drug Regimen Study
by Zacks Equity Research
Glaxo's (GSK) ViiV Healthcare commences phase III study on combo regimen of dolutegravir and lamivudine for maintenance of viral suppression in HIV-1 infection patients treated with TAF-based regimen.
Glaxo (GSK) Earnings and Revenues Surpass Estimates in Q4
by Zacks Equity Research
Glaxo's (GSK) Q4 earnings and revenues beat estimates. In the event of Advair generic introduction in the U.S. market by mid 2018, Glaxo expects adjusted EPS to be flat to down at CER in 2018.